Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Target Oncol. 2020 Dec;15(6):787-790. doi: 10.1007/s11523-020-00776-0.
SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and patients with non-small cell lung cancer (NSCLC). SB8 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with metastatic or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles.
SB8 是贝伐珠单抗的一种生物类似药，在欧盟被批准用于与贝伐珠单抗相同类型的癌症。SB8 具有与参照贝伐珠单抗相似的理化特性和药效动力学特性，在健康志愿者和非小细胞肺癌（NSCLC）患者中显示出药代动力学等效性。SB8 在转移性或复发性非鳞状 NSCLC 患者中的临床疗效与参照贝伐珠单抗相当，具有相似的耐受性、安全性和免疫原性特征。
